hematologic patients
Conditions
Interventions
Case series:no
Sponsors
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with signing of informed consent and confirming to enrollment; 2. Length of stay >72h 3. Patients experience agranulocytosis or neutrophil count (ANC)was expected to decrease to <= 0.5*10^9/L within the next 48 hours, 4. Voriconazole was administered at least for 3 days 5. Male or femaleaged 15-70years and 12 to 14 years of age weighing greater than or equal to 50 kg.
Exclusion criteria
Exclusion criteria: (1) There was evidence of active fungal infection within 3 weeks before enrollment. (2) History of allergic to voriconazole; (3) Drug intolerance; don't obey the medication guide; (4) The severe liver function and renal function; (5) With acute hepatitis or chronic liver disease; (6) Pregnant or lactating women; (7) Combination of rifampicin and isoniazid phenytoin, carbamazepine, long-acting barbiturate;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Voriconazole plasma concentration;the polymorphism of CYP2C19 gene; | — |
Secondary
| Measure | Time frame |
|---|---|
| breakthrough infection rate;adverse event incidenceciyao; | — |
Contacts
Public ContactJIANG,ErLie
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Outcome results
None listed